? Studies of the molecular basis of Alzheimer's disease (AD) exemplify the increasingly blurred distinction between basic and applied biomedical research. Genetic, biochemical, cell biological and animal modeling studies all support the hypothesis that accumulation of amyloid beta-protein (AB) causes AD, but it is not known why cerebral AB levels are elevated in the vast majority of AD patients. While great attention has been focused on the mechanisms of AB production, only a small number of cases is known to involve heightened production. Therefore, many cases of typical (late-onset) AD could be caused by faulty clearance of a peptide that is made at normal levels throughout life. In this competing renewal application, we wish to continue to pursue two hypotheses: (a) that defects in proteases which normally degrade AB may underlie some or many cases of familial and """"""""sporadic"""""""" late-onset AD; and (b) that whether or not this turns out to be true, subtly activating or disinhibiting such proteases could lower brain AB levels therapeutically. Addressing this previously understudied topic requires a thorough understanding of which proteases regulate steady-state AB levels in vivo and how they do so. To this end, we propose four interrelated Specific Aims: 1. To test whether chronic dysfunction of insulin-degrading enzyme ODE) leads to decreased AB degradation and cerebral AB accumulation in vivo in two compelling models: the GK rat, which develops type II diabetes caused by missense mutations in IDE, and a newly generated IDE knock-out mouse; 2. To quantify the relative roles of the 3 best characterized AB-degrading proteases -- neprilysin, IDE and uPA/plasminogen -- in cerebral AB economy by comparing their effects in the progeny of the relevant transgenic and knock-out mice bred to APP transgenic mice; 3. To elucidate the normal cell biology and membrane trafficking of lDE that enables it to mediate the degradation of both extracellular/intraluminal substrates (e.g., insulin, amylin, AB) and cytosolic substrates (e.g., the APP intracellular domain); and 4. To use a chemical biology approach to identify small-molecule activators and inhibitors of IDE and neprilysin as mechanistic and therapeutic tools. The proposed experiments are based on extensive preliminary data, including the establishment of the necessary rodent models, and will allow us to extend a new line of investigation in the AD field that has emanated in part from this grant. We believe the results could have broad implications for the pathogenesis and treatment of AD as well as for peptide turnover in the brain and the fundamental cell biology of proteases. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG012749-10
Application #
6881147
Study Section
Special Emphasis Panel (ZRG1-MDCN-1 (01))
Program Officer
Snyder, Stephen D
Project Start
1995-01-01
Project End
2008-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
10
Fiscal Year
2005
Total Cost
$366,418
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Yang, Ting; Hong, Soyon; O'Malley, Tiernan et al. (2013) New ELISAs with high specificity for soluble oligomers of amyloid ?-protein detect natural A? oligomers in human brain but not CSF. Alzheimers Dement 9:99-112
Holmes, Oliver; Paturi, Swetha; Ye, Wenjuan et al. (2012) Effects of membrane lipids on the activity and processivity of purified ýý-secretase. Biochemistry 51:3565-75
Wang, Xinnan; Winter, Dominic; Ashrafi, Ghazaleh et al. (2011) PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147:893-906
Meissner, Cathrin; Lorenz, Holger; Weihofen, Andreas et al. (2011) The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 trafficking. J Neurochem 117:856-67
Hong, Soyon; Quintero-Monzon, Omar; Ostaszewski, Beth L et al. (2011) Dynamic analysis of amyloid ?-protein in behaving mice reveals opposing changes in ISF versus parenchymal A? during age-related plaque formation. J Neurosci 31:15861-9
Sala Frigerio, Carlo; Fadeeva, Julia V; Minogue, Aedin M et al. (2010) beta-Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. FEBS J 277:1503-18
Leissring, Malcolm A; Malito, Enrico; Hedouin, Sabrine et al. (2010) Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One 5:e10504
Espuny-Camacho, Ira; Dominguez, Diana; Merchiers, Pascal et al. (2010) Peroxisome proliferator-activated receptor gamma enhances the activity of an insulin degrading enzyme-like metalloprotease for amyloid-beta clearance. J Alzheimers Dis 20:1119-32
Cabrol, Christelle; Huzarska, Malwina A; Dinolfo, Christopher et al. (2009) Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One 4:e5274
Hemming, Matthew L; Elias, Joshua E; Gygi, Steven P et al. (2009) Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One 4:e8477

Showing the most recent 10 out of 50 publications